Anthracycline is a type of antibiotic that comes from certain types of Streptomyces bacteria. Anthracyclines are used to treat many types of cancer. Anthracyclines damage the DNA in cancer cells, causing them to die. Daunorubicin, doxorubicin, and epirubicin are anthracyclines.
Imagine surviving cancer only to learn the drug that saved your life has introduced a completely different health risk: heart failure.
The American College of Cardiology will host the annual Advancing the Cardiovascular Care of the Oncology Patient course on April 14-16, 2023, in Washington, DC.
Anthracyclines are a class of chemotherapies effective in treating many forms of cancer, including leukemias, lymphomas and breast cancer.
Researchers at Indiana University School of Medicine are learning more about ways to prevent serious side effects from chemotherapy used to treat breast cancer patients.
Researchers at Memorial Sloan Kettering Cancer Center (MSKCC) in New York have discovered that common cancer treatments, such as radiotherapy or anthracycline drugs, cause long-term damage to heart tissue by activating a key inflammatory signaling pathway.
Researchers at Penn State have successfully 3D bioprinted breast cancer tumors and treated them in a breakthrough study to better understand the disease that is one of the leading causes of mortality worldwide.
In a new study, researchers evaluated the impact of the SARS-CoV-2 pandemic on the diagnosis and treatment of classical Hodgkin lymphoma (cHL) patients in Istanbul, Turkey.
Giving standard chemotherapy drugs in a specific sequence for some types of metastatic breast cancer can help reduce overall costs and improve the value of care while preserving quality of life, according to a study led by UNC Lineberger Comprehensive Cancer Center and UNC Gillings School of Global Public Health researchers.
The first European Society of Cardiology Guideline on cardio-oncology is published online today in European Heart Journal.
An innovative proteomics-based model that predicts the risk of cardiovascular events with higher accuracy than current clinical models.
A study conducted in rats suggests that taking vitamin C may help to counteract the muscle atrophy that is a common side effect of the chemotherapy drug doxorubicin.
A multidisciplinary team of researchers from Roswell Park Comprehensive Cancer Center and Kaiser Permanente Northern California have identified the first pharmacogenomic marker for anthracyclines and HER2-targeting drugs, two commonly used breast cancer chemotherapies.
A team of investigators have discovered a genomic variant that may help clinicians predict which patients will experience cardiotoxicity from a widely used chemotherapy drug, according to a Northwestern Medicine study published in Circulation.
A clinical trial has found that the combination of all-trans retinoic acid, which is a metabolite of vitamin A, and arsenic trioxide is highly effective in children with standard- and high-risk acute promyelocytic leukemia, or APL.
Elevated allostatic load was associated with a lower likelihood of completing chemotherapy and a lower overall survival rate in patients with lymph node-positive or high-risk lymph node-negative HER2-negative breast cancer, according to results presented at the 14th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved, held online October 6-8, 2021.
A research team by Prof. YANG Wulin and DAI Haiming from the Hefei Institutes of Physical Science (HFIPS) of the Chinese Academy of Sciences recently proposed a genetic classifier that can predict the sensitivity of neoadjuvant chemotherapy for breast cancer in the field of tumor molecular markers.
Luisa Iruela-Arispe, PhD, the Stephen Walter Ranson Professor of Cell Biology and chair of Cell and Developmental Biology, is the North American coordinator for an international collaboration that has received a five-year, $7 million Transatlantic Networks of Excellence Program award from the Leducq Foundation.
Cancer patients are a vulnerable population prone to develop cardiovascular complications. Among other factors, some anticancer therapies can induce adverse cardiovascular effects.
Adding an immune checkpoint inhibitor to anti-HER2 treatment in breast cancer does not improve pathological complete response (pCR), according to the primary analysis of the IMpassion050 trial presented today during the ESMO Virtual Plenary.
Male breast cancer patients were found to have a high prevalence of cardiovascular conditions, in a small study of this rare patient population presented at the American College of Cardiology's Advancing the Cardiovascular Care of the Oncology Patient Virtual course.